The observed safety profile was similar in the infliximab-dyyb and placebo groups, according to the safety analysis results, with the most frequent side effects being COVID-19, injection site reaction, arthralgia, anemia, abdominal pain, and elevated alanine aminotransferase [115]. This evidence concerns the gene GPT and COVID-19.